Loading clinical trials...

Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2 | Clinical Trials | Clareo Health

UNKNOWNNA

Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2

NCT05843682•University of Sao Paulo General Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the effectiveness of the use of artificial intelligence in home monitoring in patients with uncontrolled arterial hypertension.

Detailed Description

Arterial hypertension (AH) is one of the most important cardiovascular risk factors, accounting for 13.5% of all deaths worldwide. Mobile health technologies have been applied as an important tool to improve patient engagement and blood pressure (BP) control, as an alternative approach to remote monitoring of hypertensive patients. Therefore, it is essential to help patients adopt healthy measures to assist in the daily control of BP. As the barriers to therapeutic adherence are complex and varied, solutions to improve adherence at the population level should be multifactorial. Therefore, the use of an application elaborated by artificial intelligence adapted to individual needs and customs, can help in improving therapeutic adherence and provide better bp control in patients with uncontrolled hypertension.

Eligibility

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Primary arterial hypertension in drug treatment with at least 3 classes of antihypertensive drugs in optimized dose
•2. Aged between 20 and 65 years
•3. Blood pressure of the office ≥ 140 and/or 90 mmHg
•4. Facilities to use mobile and apps

Exclusion Criteria

•1. Stroke sequelae
•2. Cognitive dysfunction

Locations (1)

Heart Institute (InCor), Hospital das Clinicas do HCFMUSP

São Paulo, Brazil

Key Dates

Start Date

October 7, 2022

Primary Completion Date

August 31, 2023

Completion Date

February 29, 2024

Last Updated

May 6, 2023

Enrollment

100

ACTUAL participants

Conditions

Essential HypertensionMetabolic Cardiovascular SyndromeHeart Disease Risk Factors

Interventions

Using the Avatr App

DEVICE

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

NCT06823947

Healthy Volunteers Essential Hypertension

View study

RECRUITINGPHASE1

Metabolic Effects of Angiotensin-(1-7)

NCT02646475

ObesityInsulin Resistance+2 more

View study

ACTIVE_NOT_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 6, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2

Inclusion Criteria

Exclusion Criteria

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

Metabolic Effects of Angiotensin-(1-7)

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Mat Pilates With Paced Breathing Versus Diaphragmatic Breathing in Stage II Hypertension

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions